Bladder Cancer Clinical Trials | Norton Healthcare Louisville, Ky.

Bladder Cancer and Urothelial Cancer Clinical Trials

Norton Cancer Institute is at the forefront of cancer treatment research. As principal investigators on numerous trials, our specialist physicians have access to innovative treatments and numerous bladder cancer clinical trials.

Learn more about participating in a clinical trial at Norton Healthcare.

Active bladder cancer and urothelial cancer clinical trials include:

Genitourinary Cancer

A phase III, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab (anti-pd-l1 antibody) in combination with gemcitabine/carboplatin versus gemcitabine/carboplatin alone in patients with untreated locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-based therapy

Genitourinary Cancer

A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

Genitourinary Cancer

A Phase Ib/II Open Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Locally Advanced Or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy (MORPHEUS-mUC)

Genitourinary Cancer

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma

Genitourinary Cancer

A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder […]

Genitourinary Cancer

A Phase III, Randomized, Open Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care […]

Genitourinary Cancer

An open-label multi-cohort Phase 1b/2 study of derazantinib and atezolizumab in patients with urothelial cancer expressing activating molecular FGFR aberrations (FIDES-02)

Cancer – 4673

Appointments

Cancer care that isn’t too far from home.

(502) 629-HOPE (4673)


Request an Appointment Online

Clinical trials

Clinical Trials

Learn more about clinical trials at Norton Healthcare
(502) 629-3500

On-site genomic testing at Norton Cancer Institute allows fast and precise treatment

Thanks to the Steven Vanover Foundation and other caring community supporters, Norton Cancer Institute now has specialized laboratory capabilities and equipment to perform on-site genomic testing. This highly specialized testing makes it possible to diagnose […]

Read Full Story

Cancer during pandemic, quarantine

A few months ago, when Americans began feeling the effects of the COVID-19 pandemic, state mandates required a focus on urgent and emergency care. Along with patients’ own concerns about being in a health care setting due […]

Read Full Story

New technology reduces side effects and allows for fewer, but stronger, prostate cancer radiation treatments

For the more than 60,000 men each year whose prostate cancer is treated with radiation therapy, the close quarters around the prostate and rectum meant that prostate radiation treatments used to be delivered more frequently […]

Read Full Story

Answers to questions Norton Cancer Institute patients may have about coronavirus

As a cancer patient or someone who has completed treatment, you may be at greater risk from the coronavirus that causes COVID-19. Norton Cancer Institute and all of Norton Healthcare have developed a series of […]

Read Full Story

Emily Carr knew what the issue was — she just had to keep pushing

When Emily Carr began experiencing a baffling array of symptoms — pain when she stood up, dizziness when she leaned over, severe migraines and memory loss — she thought it could be a brain tumor. […]

Read Full Story
Related Stories

On-site genomic testing at Norton Cancer Institute allows fast and precise treatment

Thanks to the Steven Vanover Foundation and other caring community supporters, Norton Cancer Institute now has specialized laboratory capabilities and equipment to perform on-site genomic testing. This highly specialized testing makes it possible to diagnose […]

Read Full Story

Cancer during pandemic, quarantine

A few months ago, when Americans began feeling the effects of the COVID-19 pandemic, state mandates required a focus on urgent and emergency care. Along with patients’ own concerns about being in a health care setting due […]

Read Full Story

New technology reduces side effects and allows for fewer, but stronger, prostate cancer radiation treatments

For the more than 60,000 men each year whose prostate cancer is treated with radiation therapy, the close quarters around the prostate and rectum meant that prostate radiation treatments used to be delivered more frequently […]

Read Full Story

Answers to questions Norton Cancer Institute patients may have about coronavirus

As a cancer patient or someone who has completed treatment, you may be at greater risk from the coronavirus that causes COVID-19. Norton Cancer Institute and all of Norton Healthcare have developed a series of […]

Read Full Story

Emily Carr knew what the issue was — she just had to keep pushing

When Emily Carr began experiencing a baffling array of symptoms — pain when she stood up, dizziness when she leaned over, severe migraines and memory loss — she thought it could be a brain tumor. […]

Read Full Story

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.